. 2007 Apr 24;98(7):1113–1119. doi: 10.1111/j.1349-7006.2007.00498.x

Table 1.

Immune response during the therapy

Patient number	Dose of TS‐1 (mg/m²/day)	Peptide	Anti‐peptide cellular response ^†			Anti‐peptide IgG ^‡			Best clinical response	Follow up (M)	Prognosis
Patient number	Dose of TS‐1 (mg/m²/day)	Peptide	Pre	Post (sixth)	Increase after vaccine	Pre	Post (sixth)	Increase after vaccine	Best clinical response	Follow up (M)	Prognosis
1	80	SART3 109–118	0	0	–	129	13 656	+	PD	5	Dead
		CypB 91–99	0	212	+	48	56	–
		Lck 488–497	0	23	–	26	475	+
		MRP3 1293–1302	0	153	+	29	40	–
2	80	SART3 302–310	0	275	+	113	2986	+	SD	17	Alive
		Lck 246–254	0	221	+	122	174	–
		WHS 103–111	0	1253	+	212	250	–
		HNR 140–148	0	0	–	114	115	–
3	80	Lck 486–494	0	222	+	696	1009	+	PD	11	Dead
		MRP3 1293–1302	0	0	–	144	301	+
		PAP 213–221	0	0	–	317	4696	+
		EZH2 291–299	0	0	–	400	10 329	+
4	40	SART3 109–118	15	188	+	356	9135	+	PD	30	Alive
4	40	CEA 390–399	0	0	–	13	19	–	PD	30	Alive
5	40	SART3 93–101	58	0	–	219	166	–	PD	5	Dead
		Lck 486–494	89	0	–	209	165	–
		MRP3 1293–1302	0	0	–	303	247	–
		PSCA 76–84	60	0	–	144	120	–
6	40	SART3 109–118	0	60	+	543	103	–	PD	7	Dead
		MRP3 1293–1302	0	0	–	224	142	–
		PAP 213–221	0	0	–	819	266	–
		CEA 425–433	9	0	–	195	67	–
7	20	MAP 294–302	0	0	–	104	1993	+	SD	8	Dead
		UBE 43–51	0	0	–	207	24 391	+
		EIF 51–59	56	0	–	40	156	+
		EGFR 479–488	0	0	–	112	276	+
8	20	UBE 43–51	0	0	–	580	20 163	+	PD	15	Dead
		PSA 170–178	729	0	–	499	990	–
		HER2/neu 484–493	146	0	–	477	665	–
		CEA 605–613	0	0	–	831	23 694	+
9	0	SART2 93–101	0	388	+	51	1649	+	SD	25	Alive
		SART3 109–118	0	0	–	594	481	–
		Lck 488–497	0	0	–	100	361	+
		MRP3 1293–1302	0	0	–	167	932	+
10	0	SART3 109–118	0	0	–	420	1838	+	PD	5	Dead
		MRP3 1293–1302	115	45	–	167	1399	+
		CypB 91–99	314	0	–	119	779	+
		PSA 248–257	160	0	–	124	149	–
11	0	Lck 422–430	0	172	+	120	115	–	SD	17	Alive
		MAP 294–302	0	0	–	48	248	+
		UBE 43–51	348	0	–	91	113	–
		EIF 51–59	227	0	–	26	2462	+

^{^†}

Values indicate interferon (IFN)‐γ production of peptide‐stimulated peripheral blood mononuclear cells (PBMC) reactive to the corresponding peptide. An increase in IFN‐γ production after vaccination was judged positive when the level of IFN‐γ production was more than 50 pg/mL and showed an at least two‐fold increase after the sixth vaccination.

^{^‡}

^‡ Values indicate the fluorescence intensity of IgG reactive to the corresponding peptide. An increase in fluorescence intensity after vaccination was judged positive when the level increased more than two‐fold after the sixth vaccination. PD, progressive disease; PR, partial response; SD, stable disease.